INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation Meeting Abstract
| Authors: | Mellinghoff, I. K.; Van den Bent, M. J.; Clarke, J. L.; Maher, E. A.; Peters, K. B.; Touat, M.; De Groot, J. F.; De La Fuente, M. I.; Arrillaga-Romany, I.; Wick, W.; Ellingson, B. M.; Schoenfeld, S.; Tai, F.; Le, K.; Lu, M.; Steelman, L.; Hassan, I.; Pandya, S. S.; Wen, P. Y.; Cloughesy, T. F. |
| Abstract Title: | INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309054 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS2574 |
| Notes: | Meeting Abstract: TPS2574 -- Source: Wos |
